Pharnext S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALPHA.PA research report →
About the company
Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm dedicated to creating treatments for a range of neurodegenerative disorders, encompassing both rare (orphan) and common forms. Its pipeline features SYNGILITY, which has advanced through Phase III trials for Charcot-Marie-Tooth disease type 1A (CMT1A). Additionally, PXT864 has concluded Phase II clinical studies for Alzheimer's disease, and is also being explored for its potential in Parkinson's disease and amyotrophic lateral sclerosis (ALS).
- CEO
- Hugo Brugiere
- IPO
- 2016
- Employees
- 23
- HQ
- Issy-les-Moulineaux, FR
Price Chart
- Market Cap
- $1.19K
- P/E
- -0.00
- P/S
- 0.12
- P/B
- -0.00
- EV/EBITDA
- -1.02
- Div Yield
- 0.00%
- Gross Margin
- -193388.50%
- Op Margin
- -238875.82%
- Net Margin
- -275174.20%
- ROE
- 82.57%
- ROIC
- 435.79%
- Revenue
- $10.00K · 1692.11%
- Net Income
- $-27,517,420 · 28.43%
- EPS
- $-196.55 · 98.11%
- Op Income
- $-23,887,582
- FCF YoY
- 100.00%
- 52W High
- $2.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.01
- Beta
- -313.29
- Avg Volume
- 0
Get TickerSpark's AI analysis on ALPHA.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ALPHA.PA coverage
Recent articles, reports, and earnings notes.
No research on ALPHA.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALPHA.PA report →